InspireMD touts 2-year CGuard EPS results

This article was originally published here


InspireMD (NYSE:NSPR) this week released two-year results from the Paradigm 101 clinical study of its CGuard embolic protection system.

Results from the trial were initially presented at the 2017 VEITH Symposium in New York last month.

In the investigator-led study, researchers examined the use of the CGuard EPS system in 101 patients with symptomatic or high-risk asymptomatic carotid artery stenosis. Data from the study indicated that there were no deaths, major stroke or myocardial infarctions as a result of periprocedural or postprocedural interventions at at two years.

InspireMD said that the results were consistent with other CGuard EPS trials including the Carenet, Iron-Guard, Wissgott and Casana studies.

“We are excited to see Prof. Musialek’s report out on the long-term follow-up data from the Paradigm study, which represents the longest known clinical follow-up with any such carotid devices to date. This is just another piece of data that continues to reinforce the potential benefits of CGuard EPS. The 24 month follow-up data from this trial simply confirms the sustained long term benefit CGuard could provide to patients with carotid artery disease,” CEO James Barry said in a press release.

In October, InspireMD touted an independent clinical trial in Russia pitting its CGuard embolic protection device against the Rx Acculink carotid stent made by Abbott (NYSE:ABT).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply